Regulations.gov document
Demonstrating Bioequivalence for Soluble Powder Oral Dosage Form Products and Type A…
Notice · FDA-2019-D-3764 · posted Sep 30, 2019
Key facts
| Document ID | FDA-2019-D-3764-0001 |
|---|---|
| Title | Demonstrating Bioequivalence for Soluble Powder Oral Dosage Form Products and Type A Medicated Articles Manufactured From Active Pharmaceutical Ingredients Considered To Be Soluble in Aqueous Media; Draft Guidance for Industry; Availability |
| Document type | Notice |
| Subtype | Notice of Availability |
| Agency | FDA |
| Docket | FDA-2019-D-3764 |
| Posted | Sep 30, 2019 |
| Federal Register citation | 84 FR 51595 |
| FR document number | 2019-21202 |
| Comment period opens | Sep 30, 2019 |
| Comments due | Nov 30, 2019 |
| Effective date | Sep 30, 2019 |
At a glance
- 1–9 Pages
- No Open for comment
- None Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: